السوق العالمية لتسلسل بيسلفيت الجينوم الكامل (WGBS) - اتجاهات الصناعة والتوقعات حتى عام 2029

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL WHOLE GENOME BISULFITE SEQUENCING (WGBS) MARKET MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATION

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 KEY TAKEAWAYS

2.2 ARRIVING AT THE GLOBAL WHOLE GENOME BISULFITE SEQUENCING (WGBS) MARKET SIZE

2.2.1 VENDOR POSITIONING GRID

2.2.2 TECHNOLOGY LIFE LINE CURVE

2.2.3 TRIPOD DATA VALIDATION MODEL

2.2.4 MARKET GUIDE

2.2.5 MULTIVARIATE MODELLING

2.2.6 TOP TO BOTTOM ANALYSIS

2.2.7 CHALLENGE MATRIX

2.2.8 APPLICATION COVERAGE GRID

2.2.9 STANDARDS OF MEASUREMENT

2.2.10 VENDOR SHARE ANALYSIS

2.2.11 SALES VOLUME DATA

2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS

2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES

2.3 GLOBAL WHOLE GENOME BISULFITE SEQUENCING (WGBS) MARKET: RESEARCH SNAPSHOT

2.4 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 CHALLENGES

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

5.1 PESTEL ANALYSIS

5.2 PORTER’S FIVE FORCES MODEL

6 INDUSTRY INSIGHTS

6.1 MICRO AND MACRO ECONOMIC FACTORS

6.2 PENETRATION AND GROWTH PROSPECT MAPPING

6.3 KEY PRICING STRATEGIES

6.4 INTERVIEWS WITH SPECIALIST

6.5 ANALYIS AND RECOMMENDATION

7 COST ANALYSIS BREAKDOWN

8 TECHNONLOGY ROADMAP

9 INNOVATION TRACKER AND STRATEGIC ANALYSIS

9.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS

9.1.1 JOINT VENTURES

9.1.2 MERGERS AND ACQUISITIONS

9.1.3 LICENSING AND PARTNERSHIP

9.1.4 TECHNOLOGY COLLABORATIONS

9.1.5 STRATEGIC DIVESTMENTS

9.2 NUMBER OF PRODUCTS IN DEVELOPMENT

9.3 STAGE OF DEVELOPMENT

9.4 TIMELINES AND MILESTONES

9.5 INNOVATION STRATEGIES AND METHODOLOGIES

9.6 RISK ASSESSMENT AND MITIGATION

9.7 FUTURE OUTLOOK

10 REGULATORY COMPLIANCE

10.1 REGULATORY AUTHORITIES

10.2 REGULATORY CLASSIFICATIONS

10.2.1 CLASS I

10.2.2 CLASS II

10.2.3 CLASS III

10.3 REGULATORY SUBMISSIONS

10.4 INTERNATIONAL HARMONIZATION

10.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS

10.6 REGULATORY CHALLENGES AND STRATEGIES

11 REIMBURSEMENT FRAMEWORK

12 VALUE CHAIN ANALYSIS

13 HEALTHCARE ECONOMY

13.1 HEALTHCARE EXPENDITURE

13.2 CAPITAL EXPENDITURE

13.3 CAPEX TRENDS

13.4 CAPEX ALLOCATION

13.5 FUNDING SOURCES

13.6 INDUSTRY BENCHMARKS

13.7 GDP RATION IN OVERALL GDP

13.8 HEALTHCARE SYSTEM STRUCTURE

13.9 GOVERNMENT POLICIES

13.1 ECONOMIC DEVELOPMENT

14 GLOBAL WHOLE GENOME BISULFITE SEQUENCING (WGBS) MARKET, BY PRODUCT AND SERVICES

14.1 OVERVIEW

14.2 PRODUCT

14.2.1 INSTRUMENTS

14.2.1.1. BY MODALITY

14.2.1.1.1. BENCHTOP

14.2.1.1.1.1 ASP (IN USD)

14.2.1.1.1.2 MARKET VOLUME (IN UNITS)

14.2.1.1.1.3 MARKET VALUE (IN USD)

14.2.1.1.2. STANDALONE

14.2.1.1.2.1 ASP (IN USD)

14.2.1.1.2.2 MARKET VOLUME (IN UNITS)

14.2.1.1.2.3 MARKET VALUE (IN USD)

14.2.1.1.3. PORTABLE

14.2.1.1.3.1 ASP (IN USD)

14.2.1.1.3.2 MARKET VOLUME (IN UNITS)

14.2.1.1.3.3 MARKET VALUE (IN USD)

14.2.1.2. BY MODE

14.2.1.2.1. AUTOMATIC

14.2.1.2.1.1 ASP (IN USD)

14.2.1.2.1.2 MARKET VOLUME (IN UNITS)

14.2.1.2.1.3 MARKET VALUE (IN USD)

14.2.1.2.2. MANUAL

14.2.1.2.2.1 ASP (IN USD)

14.2.1.2.2.2 MARKET VOLUME (IN UNITS)

14.2.1.2.2.3 MARKET VALUE (IN USD)

14.2.1.3. BY TYPE

14.2.1.3.1. PCR INSTRUMENTS

14.2.1.3.1.1 QPCR INSTRUMENTS

14.2.1.3.1.1.1. ASP (IN USD)

14.2.1.3.1.1.2. MARKET VOLUME (IN UNITS)

14.2.1.3.1.1.3. MARKET VALUE (IN USD)

14.2.1.3.1.2 REVERSE TRANSCRIPTASE (RT-PCR)

14.2.1.3.1.2.1. ASP (IN USD)

14.2.1.3.1.2.2. MARKET VOLUME (IN UNITS)

14.2.1.3.1.2.3. MARKET VALUE (IN USD)

14.2.1.3.1.3 MULTIPLEX PCR

14.2.1.3.1.3.1. ASP (IN USD)

14.2.1.3.1.3.2. MARKET VOLUME (IN UNITS)

14.2.1.3.1.3.3. MARKET VALUE (IN USD)

14.2.1.3.1.4 NESTED PCR

14.2.1.3.1.4.1. ASP (IN USD)

14.2.1.3.1.4.2. MARKET VOLUME (IN UNITS)

14.2.1.3.1.4.3. MARKET VALUE (IN USD)

14.2.1.3.1.5 LONG-RANGE PCR

14.2.1.3.1.5.1. ASP (IN USD)

14.2.1.3.1.5.2. MARKET VOLUME (IN UNITS)

14.2.1.3.1.5.3. MARKET VALUE (IN USD)

14.2.1.3.1.6 SINGLE CELL PCR

14.2.1.3.1.6.1. ASP (IN USD)

14.2.1.3.1.6.2. MARKET VOLUME (IN UNITS)

14.2.1.3.1.6.3. MARKET VALUE (IN USD)

14.2.1.3.1.7 OTHERS

14.2.1.3.2. MICROCENTRIFUGE

14.2.1.3.2.1 ASP (IN USD)

14.2.1.3.2.2 MARKET VOLUME (IN UNITS)

14.2.1.3.2.3 MARKET VALUE (IN USD)

14.2.1.3.3. TRANSILLUMINATOR

14.2.1.3.3.1 ASP (IN USD)

14.2.1.3.3.2 MARKET VOLUME (IN UNITS)

14.2.1.3.3.3 MARKET VALUE (IN USD)

14.2.1.3.4. ELECTROPHORESIS UNIT

14.2.1.3.4.1 ASP (IN USD)

14.2.1.3.4.2 MARKET VOLUME (IN UNITS)

14.2.1.3.4.3 MARKET VALUE (IN USD)

14.2.1.3.5. GEL TRAYS AND TANK

14.2.1.3.5.1 ASP (IN USD)

14.2.1.3.5.2 MARKET VOLUME (IN UNITS)

14.2.1.3.5.3 MARKET VALUE (IN USD)

14.2.1.3.6. OTHERS

14.2.2 CONSUMABLES

14.2.2.1. KITS

14.2.2.1.1. BISULFITE KIT

14.2.2.1.2. DNA PURIFICATION KIT

14.2.2.1.2.1 ASP (IN USD)

14.2.2.1.2.2 MARKET VOLUME (IN UNITS)

14.2.2.1.2.3 MARKET VALUE (IN USD)

14.2.2.1.3. BISULFITE TREATMENT OF GENOMIC DNA

14.2.2.1.3.1 ASP (IN USD)

14.2.2.1.3.2 MARKET VOLUME (IN UNITS)

14.2.2.1.3.3 MARKET VALUE (IN USD)

14.2.2.1.4. SAMPLE PREPARATION KIT

14.2.2.1.4.1 ASP (IN USD)

14.2.2.1.4.2 MARKET VOLUME (IN UNITS)

14.2.2.1.4.3 MARKET VALUE (IN USD)

14.2.2.1.5. DNA EXTRACTION KIT

14.2.2.1.5.1 ASP (IN USD)

14.2.2.1.5.2 MARKET VOLUME (IN UNITS)

14.2.2.1.5.3 MARKET VALUE (IN USD)

14.2.2.1.5.4

14.2.2.1.6. DNA REPAIR KIT

14.2.2.1.6.1 ASP (IN USD)

14.2.2.1.6.2 MARKET VOLUME (IN UNITS)

14.2.2.1.6.3 MARKET VALUE (IN USD)

14.2.2.1.7. OTHERS

14.2.2.2. BUFFER

14.2.2.2.1. ASP (IN USD)

14.2.2.2.2. MARKET VOLUME (IN UNITS)

14.2.2.2.3. MARKET VALUE (IN USD)

14.2.2.3. GELS

14.2.2.3.1. ASP (IN USD)

14.2.2.3.2. MARKET VOLUME (IN UNITS)

14.2.2.3.3. MARKET VALUE (IN USD)

14.2.2.4. TUBES

14.2.2.4.1. ASP (IN USD)

14.2.2.4.2. MARKET VOLUME (IN UNITS)

14.2.2.4.3. MARKET VALUE (IN USD)

14.2.2.5. DYES

14.2.2.5.1. ASP (IN USD)

14.2.2.5.2. MARKET VOLUME (IN UNITS)

14.2.2.5.3. MARKET VALUE (IN USD)

14.2.2.6. OTHERS

14.3 SERVICES

14.3.1 BISULFITE TREATMENT/ CONVERSION

14.3.1.1. ASP (IN USD)

14.3.1.2. MARKET VOLUME (NUMBER OF TEST)

14.3.1.3. MARKET VALUE (IN USD)

14.3.2 DATA ANALYSIS/BIOINFORMATICS

14.3.2.1. DATA MINING

14.3.2.1.1. ASP (IN USD)

14.3.2.1.2. MARKET VOLUME (NUMBER OF TEST)

14.3.2.1.3. MARKET VALUE (IN USD)

14.3.2.2. STANDARD

14.3.2.2.1. ASP (IN USD)

14.3.2.2.2. MARKET VOLUME (NUMBER OF TEST)

14.3.2.2.3. MARKET VALUE (IN USD)

14.3.2.3. DIFFERENTIAL METHYLATION ANALYSIS

14.3.2.3.1. ASP (IN USD)

14.3.2.3.2. MARKET VOLUME (NUMBER OF TEST)

14.3.2.3.3. MARKET VALUE (IN USD)

14.3.2.4. GENE ONTOLOGY TERMS ANALYSIS

14.3.2.4.1. ASP (IN USD)

14.3.2.4.2. MARKET VOLUME (NUMBER OF TEST)

14.3.2.4.3. MARKET VALUE (IN USD)

14.3.2.5. OTHERS

14.3.3 SEQUENCING & LIBRARY PREPARATION

14.3.3.1. ASP (IN USD)

14.3.3.2. MARKET VOLUME (NUMBER OF TEST)

14.3.3.3. MARKET VALUE (IN USD)

14.3.4 CUSTOM SERVICES

14.3.4.1. ASP (IN USD)

14.3.4.2. MARKET VOLUME (NUMBER OF TEST)

14.3.4.3. MARKET VALUE (IN USD)

14.3.5 OTHERS

15 GLOBAL WHOLE GENOME BISULFITE SEQUENCING MARKET, BY APPLICATION

15.1 OVERVIEW

15.2 STEM CELL APPLICATIONS

15.2.1 PRODUCT

15.2.1.1. INSTRUMENTS

15.2.1.2. CONSUMBALES

15.2.2 SERVICES

15.3 EMBRYONIC DEVELOPMENT

15.3.1 PRODUCT

15.3.1.1. INSTRUMENTS

15.3.1.2. CONSUMBALES

15.3.2 SERVICES

15.4 FORENSIC SCIENCE

15.4.1 PRODUCT

15.4.1.1. INSTRUMENTS

15.4.1.2. CONSUMBALES

15.4.2 SERVICES

15.5 EARLY DIAGNOSIS OF DISEASES

15.5.1 CANCER

15.5.1.1. BREAST CANCER

15.5.1.1.1. PRODUCT

15.5.1.1.1.1 INSTRUMENTS

15.5.1.1.1.2 CONSUMBALES

15.5.1.1.2. SERVICES

15.5.1.2. BLADDER CANCER

15.5.1.2.1. PRODUCT

15.5.1.2.1.1 INSTRUMENTS

15.5.1.2.1.2 CONSUMBALES

15.5.1.2.2. SERVICES

15.5.1.3. LYMPH CANCER

15.5.1.3.1. PRODUCT

15.5.1.3.1.1 INSTRUMENTS

15.5.1.3.1.2 CONSUMBALES

15.5.1.3.2. SERVICES

15.5.1.4. LIVER CANCER

15.5.1.4.1. PRODUCT

15.5.1.4.1.1 INSTRUMENTS

15.5.1.4.1.2 CONSUMBALES

15.5.1.4.2. SERVICES

15.5.1.5. OTHERS

15.5.2 COMPLEX DISEASES

15.5.2.1. AUTOIMMUNE

15.5.2.1.1. PRODUCT

15.5.2.1.1.1 INSTRUMENTS

15.5.2.1.1.2 CONSUMBALES

15.5.2.1.2. SERVICES

15.5.2.2. CARDIOVASCULAR

15.5.2.2.1. PRODUCT

15.5.2.2.1.1 INSTRUMENTS

15.5.2.2.1.2 CONSUMBALES

15.5.2.2.2. SERVICES

15.5.2.3. MENTAL DISORDER

15.5.2.3.1. PRODUCT

15.5.2.3.1.1 INSTRUMENTS

15.5.2.3.1.2 CONSUMBALES

15.5.2.3.2. SERVICES

15.5.2.4. GENETIC DISEASE

15.5.2.4.1. PRODUCT

15.5.2.4.1.1 INSTRUMENTS

15.5.2.4.1.2 CONSUMBALES

15.5.2.4.2. SERVICES

15.5.3 OTHERS

16 GLOBAL WHOLE GENOME BISULFITE SEQUENCING MARKET, BY WORKFLOW

16.1 OVERVIEW

16.2 LIBRARY PREPARATION

16.3 SEQUENCING

16.4 BIOINFORMATIC ANALYSIS

16.5 OTHERS

17 GLOBAL WHOLE GENOME BISULFITE SEQUENCING MARKET, BY END USER

17.1 OVERVIEW

17.2 CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS AND CONTRACT RESEARCH ORGANIZATIONS (CDMOS & CROS)

17.2.1 BY TYPE

17.2.1.1. SMALL ENTERPRIZES

17.2.1.2. LARGE ENTERPRIZES

17.2.1.3. MEDIUM ENTERPRIZES

17.2.2 BY PRODUCT AND SERVICES

17.2.2.1. PRODUCT

17.2.2.1.1. INSTRUMENTS

17.2.2.1.2. CONSUMBALES

17.2.2.2. SERVICES

17.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

17.3.1 BY TYPE

17.3.1.1. SMALL ENTERPRIZES

17.3.1.2. LARGE ENTERPRIZES

17.3.1.3. MEDIUM ENTERPRIZES

17.3.2 BY PRODUCT AND SERVICES

17.3.2.1. PRODUCT

17.3.2.1.1. INSTRUMENTS

17.3.2.1.2. CONSUMBALES

17.3.2.2. SERVICES

17.4 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES

17.4.1 BY PRODUCT AND SERVICES

17.4.1.1. PRODUCT

17.4.1.1.1. INSTRUMENTS

17.4.1.1.2. CONSUMBALES

17.4.1.2. SERVICES

17.5 OTHERS

18 GLOBAL WHOLE GENOME BISULFITE SEQUENCING MARKET, BY DISTRIBUTION CHANNEL

18.1 OVERVIEW

18.2 DIRECT TENDER

18.3 RETAIL SALES

18.3.1 OFFLINE

18.3.2 ONLINES

18.4 OTHERS

19 GLOBAL WHOLE GENOME BISULFITE SEQUENCING MARKET, BY GEOGRAPHY

19.1 GLOBAL WHOLE GENOME BISULFITE SEQUENCING MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

19.1.1 NORTH AMERICA

19.1.1.1. U.S.

19.1.1.2. CANADA

19.1.1.3. MEXICO

19.1.2 EUROPE

19.1.2.1. GERMANY

19.1.2.2. FRANCE

19.1.2.3. U.K.

19.1.2.4. HUNGARY

19.1.2.5. LITHUANIA

19.1.2.6. AUSTRIA

19.1.2.7. IRELAND

19.1.2.8. NORWAY

19.1.2.9. POLAND

19.1.2.10. ITALY

19.1.2.11. SPAIN

19.1.2.12. RUSSIA

19.1.2.13. TURKEY

19.1.2.14. BELGIUM

19.1.2.15. NETHERLANDS

19.1.2.16. SWITZERLAND

19.1.2.17. REST OF EUROPE

19.1.3 ASIA-PACIFIC

19.1.3.1. JAPAN

19.1.3.2. CHINA

19.1.3.3. SOUTH KOREA

19.1.3.4. INDIA

19.1.3.5. AUSTRALIA

19.1.3.6. SINGAPORE

19.1.3.7. THAILAND

19.1.3.8. MALAYSIA

19.1.3.9. INDONESIA

19.1.3.10. PHILIPPINES

19.1.3.11. VIETNAM

19.1.3.12. REST OF ASIA-PACIFIC

19.1.4 SOUTH AMERICA

19.1.4.1. BRAZIL

19.1.4.2. ARGENTINA

19.1.4.3. PERU

19.1.4.4. REST OF SOUTH AMERICA

19.1.5 MIDDLE EAST AND AFRICA

19.1.5.1. SOUTH AFRICA

19.1.5.2. SAUDI ARABIA

19.1.5.3. UAE

19.1.5.4. EGYPT

19.1.5.5. KUWAIT

19.1.5.6. ISRAEL

19.1.5.7. REST OF MIDDLE EAST AND AFRICA

20 GLOBAL WHOLE GENOME BISULFITE SEQUENCING MARKET, COMPANY LANDSCAPE

20.1 COMPANY SHARE ANALYSIS: GLOBAL

20.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

20.3 COMPANY SHARE ANALYSIS: EUROPE

20.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

20.5 MERGERS & ACQUISITIONS

20.6 NEW PRODUCT DEVELOPMENT & APPROVALS

20.7 EXPANSIONS

20.8 REGULATORY CHANGES

20.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

21 GLOBAL WHOLE GENOME BISULFITE SEQUENCING MARKET, SWOT AND DBMR ANALYSIS

22 GLOBAL WHOLE GENOME BISULFITE SEQUENCING MARKET, COMPANY PROFILE

22.1 ILLUMINA INC.

22.1.1 COMPANY OVERVIEW

22.1.2 REVENUE ANALYSIS

22.1.3 GEOGRAPHIC PRESENCE

22.1.4 PRODUCT PORTFOLIO

22.1.5 RECENT DEVELOPEMENTS

22.2 BERRY GENOMICS CO., LTD.

22.2.1 COMPANY OVERVIEW

22.2.2 REVENUE ANALYSIS

22.2.3 GEOGRAPHIC PRESENCE

22.2.4 PRODUCT PORTFOLIO

22.2.5 RECENT DEVELOPEMENTS

22.3 THERMO FISHER SCIENTIFIC, INC.

22.3.1 COMPANY OVERVIEW

22.3.2 REVENUE ANALYSIS

22.3.3 GEOGRAPHIC PRESENCE

22.3.4 PRODUCT PORTFOLIO

22.3.5 RECENT DEVELOPEMENTS

22.4 ZYMO RESEARCH CORPORATION.

22.4.1 COMPANY OVERVIEW

22.4.2 REVENUE ANALYSIS

22.4.3 GEOGRAPHIC PRESENCE

22.4.4 PRODUCT PORTFOLIO

22.4.5 RECENT DEVELOPEMENTS

22.5 QIAGEN

22.5.1 COMPANY OVERVIEW

22.5.2 REVENUE ANALYSIS

22.5.3 GEOGRAPHIC PRESENCE

22.5.4 PRODUCT PORTFOLIO

22.5.5 RECENT DEVELOPEMENTS

22.6 MERCK MILLIPORE

22.6.1 COMPANY OVERVIEW

22.6.2 REVENUE ANALYSIS

22.6.3 GEOGRAPHIC PRESENCE

22.6.4 PRODUCT PORTFOLIO

22.6.5 RECENT DEVELOPEMENTS

22.7 BIO-RAD LABORATORIES, INC.

22.7.1 COMPANY OVERVIEW

22.7.2 REVENUE ANALYSIS

22.7.3 GEOGRAPHIC PRESENCE

22.7.4 PRODUCT PORTFOLIO

22.7.5 RECENT DEVELOPEMENTS

22.8 F. HOFFMANN-LA ROCHE LTD.

22.8.1 COMPANY OVERVIEW

22.8.2 REVENUE ANALYSIS

22.8.3 GEOGRAPHIC PRESENCE

22.8.4 PRODUCT PORTFOLIO

22.8.5 RECENT DEVELOPMENTS

22.9 NEW ENGLAND BIOLABS

22.9.1 COMPANY OVERVIEW

22.9.2 REVENUE ANALYSIS

22.9.3 GEOGRAPHIC PRESENCE

22.9.4 PRODUCT PORTFOLIO

22.9.5 RECENT DEVELOPEMENTS

22.1 AGILENT TECHNOLOGIES, INC.

22.10.1 COMPANY OVERVIEW

22.10.2 REVENUE ANALYSIS

22.10.3 GEOGRAPHIC PRESENCE

22.10.4 PRODUCT PORTFOLIO

22.10.5 RECENT DEVELOPEMENTS

22.11 PERKINELMER, INC.

22.11.1 COMPANY OVERVIEW

22.11.2 REVENUE ANALYSIS

22.11.3 GEOGRAPHIC PRESENCE

22.11.4 PRODUCT PORTFOLIO

22.11.5 RECENT DEVELOPEMENTS

22.12 MGI TECH CO., LTD.

22.12.1 COMPANY OVERVIEW

22.12.2 REVENUE ANALYSIS

22.12.3 GEOGRAPHIC PRESENCE

22.12.4 PRODUCT PORTFOLIO

22.12.5 RECENT DEVELOPEMENTS

22.13 LUCIGEN CORPORATION

22.13.1 COMPANY OVERVIEW

22.13.2 REVENUE ANALYSIS

22.13.3 GEOGRAPHIC PRESENCE

22.13.4 PRODUCT PORTFOLIO

22.13.5 RECENT DEVELOPEMENTS

22.14 NOVOGENE CO., LTD.

22.14.1 COMPANY OVERVIEW

22.14.2 REVENUE ANALYSIS

22.14.3 GEOGRAPHIC PRESENCE

22.14.4 PRODUCT PORTFOLIO

22.14.5 RECENT DEVELOPEMENTS

22.15 OMEGA BIO-TEK, INC.

22.15.1 COMPANY OVERVIEW

22.15.2 REVENUE ANALYSIS

22.15.3 GEOGRAPHIC PRESENCE

22.15.4 PRODUCT PORTFOLIO

22.15.5 RECENT DEVELOPEMENTS

22.16 SEEGENE INC.

22.16.1 COMPANY OVERVIEW

22.16.2 REVENUE ANALYSIS

22.16.3 GEOGRAPHIC PRESENCE

22.16.4 PRODUCT PORTFOLIO

22.16.5 RECENT DEVELOPEMENTS

22.17 BIOMÉRIEUX S.A.

22.17.1 COMPANY OVERVIEW

22.17.2 REVENUE ANALYSIS

22.17.3 GEOGRAPHIC PRESENCE

22.17.4 PRODUCT PORTFOLIO

22.17.5 RECENT DEVELOPEMENTS

22.18 ABBOTT LABOROTORIES

22.18.1 COMPANY OVERVIEW

22.18.2 REVENUE ANALYSIS

22.18.3 GEOGRAPHIC PRESENCE

22.18.4 PRODUCT PORTFOLIO

22.18.5 RECENT DEVELOPEMENTS

22.19 FLUIDIGM CORPORATION

22.19.1 COMPANY OVERVIEW

22.19.2 REVENUE ANALYSIS

22.19.3 GEOGRAPHIC PRESENCE

22.19.4 PRODUCT PORTFOLIO

22.19.5 RECENT DEVELOPEMENTS

22.2 DANAHER

22.20.1 COMPANY OVERVIEW

22.20.2 REVENUE ANALYSIS

22.20.3 GEOGRAPHIC PRESENCE

22.20.4 PRODUCT PORTFOLIO

22.20.5 RECENT DEVELOPEMENTS

22.21 BECTON DICKINSON AND COMPANY

22.21.1 COMPANY OVERVIEW

22.21.2 REVENUE ANALYSIS

22.21.3 GEOGRAPHIC PRESENCE

22.21.4 PRODUCT PORTFOLIO

22.21.5 RECENT DEVELOPEMENTS

22.22 TAKARA BIO, INC.

22.22.1 COMPANY OVERVIEW

22.22.2 REVENUE ANALYSIS

22.22.3 GEOGRAPHIC PRESENCE

22.22.4 PRODUCT PORTFOLIO

22.22.5 RECENT DEVELOPEMENTS

22.23 DIAGENODE DIAGNOSTICS

22.23.1 COMPANY OVERVIEW

22.23.2 REVENUE ANALYSIS

22.23.3 GEOGRAPHIC PRESENCE

22.23.4 PRODUCT PORTFOLIO

22.23.5 RECENT DEVELOPEMENTS

22.24 DIATECH PHARMACOGENETICS S.R.L.,

22.24.1 COMPANY OVERVIEW

22.24.2 REVENUE ANALYSIS

22.24.3 GEOGRAPHIC PRESENCE

22.24.4 PRODUCT PORTFOLIO

22.24.5 RECENT DEVELOPEMENTS

22.25 ABCAM PLC

22.25.1 COMPANY OVERVIEW

22.25.2 REVENUE ANALYSIS

22.25.3 GEOGRAPHIC PRESENCE

22.25.4 PRODUCT PORTFOLIO

22.25.5 RECENT DEVELOPEMENTS

22.26 ACTIVE MOTIF,INC

22.26.1 COMPANY OVERVIEW

22.26.2 REVENUE ANALYSIS

22.26.3 GEOGRAPHIC PRESENCE

22.26.4 PRODUCT PORTFOLIO

22.26.5 RECENT DEVELOPEMENTS

22.27 SBS GENETECH

22.27.1 COMPANY OVERVIEW

22.27.2 REVENUE ANALYSIS

22.27.3 GEOGRAPHIC PRESENCE

22.27.4 PRODUCT PORTFOLIO

22.27.5 RECENT DEVELOPEMENTS

22.28 EPPENDORF

22.28.1 COMPANY OVERVIEW

22.28.2 REVENUE ANALYSIS

22.28.3 GEOGRAPHIC PRESENCE

22.28.4 PRODUCT PORTFOLIO

22.28.5 RECENT DEVELOPEMENTS

22.29 ANALYTIK JENA

22.29.1 COMPANY OVERVIEW

22.29.2 REVENUE ANALYSIS

22.29.3 GEOGRAPHIC PRESENCE

22.29.4 PRODUCT PORTFOLIO

22.29.5 RECENT DEVELOPEMENTS

22.3 EUROFINS GENOMICS

22.31 BGI

22.31.1 COMPANY OVERVIEW

22.31.2 REVENUE ANALYSIS

22.31.3 GEOGRAPHIC PRESENCE

22.31.4 PRODUCT PORTFOLIO

NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST

23 RELATED REPORTS

24 CONCLUSION

25 QUESTIONNAIRE

26 ABOUT DATA BRIDGE MARKET RESEARCH